Actively Recruiting
Optic Nerve Injury in Obstructive Sleep Apnea Patients
Led by Nanjing Medical University · Updated on 2025-06-27
80
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obstruction and apnea during sleep, leading to recurrent intermittent hypoxemia with fragmented sleep and daytime sleepiness. Due to the lack of accurate methods to evaluate blood flow, the correlation between the two is unclear and uncertain. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University and categorize them into mild, moderate, and severe OSA groups according to their apnea-hypopnea index (AHI). Participants will undergo a baseline evaluation, including polysomnography (PSG) and ophthalmologic examinations such as optic nerve and macular blood flow OCT, visual acuity, refraction, intraocular pressure, and visual fields. Eligible patients will be treated with CPAP for 3 months, after which their PSG and ophthalmologic examination-related results will be re-evaluated to assess treatment efficacy.
CONDITIONS
Official Title
Optic Nerve Injury in Obstructive Sleep Apnea Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged between 18 and 80 years
- Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) with apnea-hypopnea index of 5 or more per hour
- First-time diagnosis with no prior surgery or CPAP treatment for OSA
- Able and willing to provide informed consent for study participation
You will not qualify if you...
- History of severe stroke, cerebral hemorrhage, or neurological or psychiatric conditions affecting study results
- Active cancer or severe diseases such as severe liver or kidney problems, diagnosed diabetes with vascular complications, or major vascular diseases
- Severe chronic lung diseases including COPD, asthma, severe pulmonary hypertension, or heart failure
- Pregnancy or other conditions making study participation unsuitable
- Extremely debilitated patients or those with severe underlying conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
N
Ning Ding,MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here